Valeo Financial Advisors LLC bought a new stake in AxoGen, Inc. (NASDAQ:AXGN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,607 shares of the medical equipment provider’s stock, valued at approximately $244,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. lifted its holdings in AxoGen by 575.0% in the second quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 5,750 shares during the period. Bank of America Corp DE lifted its holdings in AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 814 shares during the period. Neuberger Berman Group LLC acquired a new position in AxoGen in the second quarter valued at $201,000. OxFORD Asset Management LLP acquired a new position in AxoGen in the third quarter valued at $270,000. Finally, Nationwide Fund Advisors lifted its holdings in AxoGen by 5.5% in the second quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after buying an additional 774 shares during the period. Institutional investors and hedge funds own 66.00% of the company’s stock.

AxoGen, Inc. (AXGN) opened at $26.20 on Wednesday. AxoGen, Inc. has a fifty-two week low of $8.25 and a fifty-two week high of $27.60. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The firm had revenue of $16.05 million for the quarter, compared to analyst estimates of $15.55 million. The business’s quarterly revenue was up 43.2% compared to the same quarter last year. sell-side analysts forecast that AxoGen, Inc. will post -0.31 earnings per share for the current year.

AXGN has been the topic of several research reports. Leerink Swann upped their price objective on shares of AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, November 21st. Lake Street Capital upped their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 21st. Roth Capital reiterated a “buy” rating and set a $21.00 price objective (up previously from $18.00) on shares of AxoGen in a report on Tuesday, September 12th. Wedbush reiterated a “buy” rating and set a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 price objective on shares of AxoGen in a report on Monday, August 21st. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. AxoGen has an average rating of “Buy” and an average price target of $26.17.

In other news, Director Jamie Mark Grooms sold 21,290 shares of the business’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $26.22, for a total transaction of $558,223.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $19.74, for a total transaction of $22,701,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,255,585 shares of company stock valued at $25,482,926. 9.33% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Valeo Financial Advisors LLC Invests $244,000 in AxoGen, Inc. (AXGN) Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/valeo-financial-advisors-llc-invests-244000-in-axogen-inc-axgn-stock/1760571.html.

AxoGen Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN).

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.